Corbus Pharmaceuticals Holding - Asset Resilience Ratio
Corbus Pharmaceuticals Holding (CRBP) has an Asset Resilience Ratio of 70.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Corbus Pharmaceuticals Holding's Asset Resilience Ratio has changed over time. Check Corbus Pharmaceuticals Holding (CRBP) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Corbus Pharmaceuticals Holding's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CRBP stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $77.00 Million | 70.31% |
| Total Liquid Assets | $77.00 Million | 70.31% |
Asset Resilience Insights
- Very High Liquidity: Corbus Pharmaceuticals Holding maintains exceptional liquid asset reserves at 70.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corbus Pharmaceuticals Holding Industry Peers by Asset Resilience Ratio
Compare Corbus Pharmaceuticals Holding's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Corbus Pharmaceuticals Holding (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Corbus Pharmaceuticals Holding.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 84.59% | $131.86 Million | $155.88 Million | +59.19pp |
| 2023-12-31 | 25.40% | $7.18 Million | $28.27 Million | -38.23pp |
| 2022-12-31 | 63.63% | $42.19 Million | $66.31 Million | -3.80pp |
| 2021-12-31 | 67.43% | $72.64 Million | $107.73 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $102.29 Million | -- |
| 2017-12-31 | 0.24% | $159.00K | $66.98 Million | -0.60pp |
| 2016-12-31 | 0.84% | $150.00K | $17.89 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $12.88 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $6.60 Million | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation o… Read more